Last update June 14, 2022

C15H24N2O4S,HCl

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Tiapride is a substituted benzamide with general properties similar to those of sulpiride. It is used in behavioral disorders, in dyskinesias (chorea), anxiety in the elderly, alcohol withdrawal syndrome, negative symptoms of psychosis and as an analgesic. Oral administration in 2 to 3 daily doses; Also intramuscularly or intravenously.

Since the last update we have not found published data on its excretion in breastmilk.

Its almost null binding to plasmatic proteins makes it likely that significant amounts will pass into breast milk; its large volume of distribution would make it difficult.

It may cause hyperprolactinemia and galactorrhea. (Greil 1985, Le Bigot 1982)

It may cause drowsiness.


See below the information of this related product:

Alternatives

  • Sulpiride (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C15H24N2O4S,HCl is Tiapride in Molecular formula.

Is written in other languages:

Groups

C15H24N2O4S,HCl belongs to these groups or families:

Tradenames

Main tradenames from several countries containing C15H24N2O4S,HCl in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 75 %
Molecular weight 365 daltons
Protein Binding ≈ 0 %
VD 1.43 l/Kg
pKa 13.23 -
Tmax 1 -2 hours
3 - 4 hours

References

  1. AEMPS. Tiaprida Ficha técnica. 2008 Full text (in our servers)
  2. Hexal. Tiapride (Tiacob). Drug Summary. 2006 Full text (in our servers)
  3. Greil W, Auberger S, Haag H, Rüther E. Tiapride: effects on tardive dyskinesia and on prolactin plasma concentrations. Neuropsychobiology. 1985;14(1):17-22. Abstract
  4. Le Bigot P. [Effect of tiapride on headache and various other types of pain]. Sem Hop. 1982 Sep 16;58(33):1908-9. French. Abstract

Total visits

557

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM